Aesther Healthcare shareholders approve all proposals for Ocean Biomedical merger

7 – Adjournment Proposal The Shareholders approved the Adjournment Proposal, as defined in the Proxy Statement, to adjourn the Special Meeting to a later date or dates, if necessary to permit further solicitation and vote of proxies if it is determined by Aesther that more time is necessary or appropriate to approve one or more Proposals at the Special Meeting. The following is a tabulation of the voting results: Common Against Abstentions Broker (24%) 0 (0%) –

2 – Charter Amendment Proposal The Shareholders approved the Charter Amendment Proposal (including the Share Increase Amendment), each as defined in the Proxy Statement, to adopt and amend the Third Amended and Restated Certificate of Incorporation of Aesther Healthcare Acquisition Corp., which shall become effective upon the Closing of the Transaction. The following is a tabulation of the voting results: Common Non-Votes 9,006,495 (24%) 10 (0.00008%) –

6 – Election of Directors Proposal The Shareholders approved the Election of Directors Proposal, as defined in the Proxy Statement, to elect eleven directors to serve staggard terms on the Aesther’s board of directors until the 2023, 2024, and 2025 annual meetings of the stockholders, respectively, and until their respective successors are duly elected and qualified. The following is a tabulation of the voting results: Common Stock: Votes For Votes Against Abstentions Broker Non-Votes 9,006,516 (76%) 2,317,396 (20%) 575,373 (4%) –

5 – Employee Stock Purchase Plan Proposal The Shareholders approved the Employee Stock Purchase Plan Proposal, as defined in the Proxy Statement, to approve the Employee Stock Purchase Plan (a copy of the 2022 Equity Incentive Plan is attached to the Proxy Statement as Annex D). The following is a tabulation of the voting results: Common Non-Votes 9,006,496 (76%) 2,317,396 (20%) 575,373 (4%) – 2

4 – Incentive Plan Proposal The Shareholders approved the Incentive Plan Proposal, as defined in the Proxy Statement, to approve the 2022 Equity Incentive Plan (a copy of the 2022 Equity Incentive Plan is attached to the Proxy Statement as Annex C). The following is a tabulation of the voting results: Common Non-Votes 8,440,398 (71%) 3,458,867 (29%) 0

Proposal 1- Business Combination Proposal The Shareholders approved the Business Combination Proposal, as defined in the Proxy Statement, to adopt and approve the Merger Agreement pursuant to which at the closing of the Transaction, Merger Sub will merge with and into Ocean Biomedical. The following is a tabulation of the voting results: Common (24%) 0

3 – Nasdaq Proposal The Shareholders approved the Nasdaq Proposal, as defined in the Proxy Statement, to approve for purposes of complying with Nasdaq Listing Rules 5635(a) and (b), the issuance of more than 20% of the issued and outstanding Class A common stock and the resulting change in control in connection with the Transaction between Aesther and White Lion Capital LLC. The following is a tabulation of the voting results: Common (24%) 0